Prometheus Anser ADA
Test Mnemonic
ANSADA
CPT Codes
- 80145 - QTY (1)
- 82542 - QTY (1)
Includes
- Serum adalimumab (ADA) concentration
- Antibody to adalimumab (ATA) concentration
Performing Laboratory
Prometheus
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Serum | SST (Gold) | Refrigerated | Ship using cold pack |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Serum | No additive (Red) | Refrigerated | Ship using cold pack |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 2 mL | Adult patients | ||||
| 0.5 mL | Pediatric patients |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | 7 days |
| Refrigerated | 9 days |
| Frozen | Unacceptable |
Days Performed
Varies
Turnaround Time
4 - 5 days
Methodology
| Name | Description |
|---|---|
| High Performance Liquid Chromatography (HPLC) |
Clinical Info
Serum concentrations of adalimumab (ADA) may vary among equally dosed patients, which can ultimately affect patient outcomes. Suboptimal levels of ADA have been linked to lower response rates in IBD patients. Additionally, some patients may develop immunogenicity to ADA by producing antibodies to adalimumab (ATA). The presence of ATA has also been associated with increased rates of infusion reactions and drug clearance leading to lower response rates. Therefore, the quantitative measurement of ADA and ATA levels in serum provides clinicians with valuable information to help them gain a better understanding of the factors that may be affecting a patient’s loss of response. The Prometheus Anser ADA test is a next generation quantitative monitoring assay that allows healthcare providers to measure and monitor serum ADA and ATA levels at any time during therapy. Incorporating therapeutic drug monitoring may clarify what factors are contributing to a patient’s loss of response and help patient management by providing information to help decide an appropriate course of action.